RADNOR, Pa., Sept. 12, 2011 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and life-threatening infectious diseases, today provided an update for its two lead programs, heptagonist PMX-60056 and defensin-mimetic antibiotic PMX-30063.
